Arvinas, a US biotechnology company based in New Haven, Connecticut, that is creating a new class of oncology drugs based on protein degradation, has hired Angela Shen as Chief Medical Officer.
Prior to joining Arvinas, Shen spent more than six years with Novartis Oncology. As a global clinical programe head, she helped launch the CTL019 (CART-19) Cell & Gene Therapy programme and built a clinical and operations team. As head of clinical evaluation for the Oncology Business Development group, she was involved in licensing in new compounds to strengthen the Novartis Oncology pipeline, including CTL019. Previously, Shen was a clinical lead at Novartis for the development of new oncology assets including panobinostat (Farydak) and inhibitors of the enzyme PI3-kinase.
At Exelixis, Shen was clinical lead for multiple drugs in early development, including cobimetinib (Cotellic), which was subsequently developed by Genentech and recently obtained FDA approval.
At Johnson & Johnson, she held a medical affairs role supporting Velcade, Doxil, Yondelis, and Procrit.
